Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...
Zacks.com on MSN1d
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...
Reuters on MSN8d
UK health system to offer cutting-edge gene therapy for sickle cell disease
Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...
GlobalData on MSN8d
NHS England to offer Casgevy for sickle cell disease patients
Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.
health.economictimes.indiatimes8d
UK health system to offer cutting-edge gene therapy for sickle cell disease
The therapy from Vertex Pharmaceuticals and CRISPR Therapeutics will cost the state-funded healthcare system around 1.65 million pounds ($2.1 million) per course. Britain's MHRA medical regulator ...